Protein biomarkers associated with pain mechanisms in osteoarthritis.

Biochemical marker Biomarker Cartilage Osteoarthritis Pain Synovium

Journal

Journal of proteomics
ISSN: 1876-7737
Titre abrégé: J Proteomics
Pays: Netherlands
ID NLM: 101475056

Informations de publication

Date de publication:
06 01 2019
Historique:
received: 31 10 2017
revised: 16 04 2018
accepted: 20 04 2018
pubmed: 29 4 2018
medline: 23 2 2020
entrez: 29 4 2018
Statut: ppublish

Résumé

Osteoarthritis (OA) is the most common arthritic disease in the world, leading to debilitating pain and destruction of joint tissues. While pain is the hallmark symptom of osteoarthritis, clear associations between pain and disease processes involved in joint deterioration are lacking. OA pain is multifactorial and may arise from multiple distinct or concurrent mechanisms, and may thus present as different pain sub-types. Several biomarkers developed to reflect important pathological processes are available, and associations between such biomarkers and OA pain may give hints to important pathological features, which have not been possible to assess using clinical, radiographic or magnetic resonance imaging techniques. This review highlights a selection of important, protein-derived biomarkers measured in body fluids from OA patients, which have been associated with different types and aspects of OA pain, and discusses the potential mechanisms behind the associations. SIGNIFICANCE: Osteoarthritis (OA) is a heterogenous disease affecting the entire joint, including cartilage, bone and synovium. While pain is the hallmark symptom of osteoarthritis, clear associations between pain and disease processes involved in joint deterioration are lacking. Thus, there is clear need for biomarkers that can accurately describe the underlying processes and distinguish between different disease and pain pathologies. In this review we discuss a selected number of biomarkers which have been directly or indirectly associated with pain mechanisms and development of pain in OA either via structural correlates or as molecular sensitizing agents. We further evaluate the challenges that the OA field faces in the development and application of biomarkers for OA pain.

Identifiants

pubmed: 29704569
pii: S1874-3919(18)30189-1
doi: 10.1016/j.jprot.2018.04.030
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-66

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Christian S Thudium (CS)

Nordic Bioscience A/S, Herlev, Denmark. Electronic address: cst@nordicbio.com.

Henrik Löfvall (H)

Nordic Bioscience A/S, Herlev, Denmark; Division of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, Lund, Sweden.

Morten A Karsdal (MA)

Nordic Bioscience A/S, Herlev, Denmark.

Anne-Christine Bay-Jensen (AC)

Nordic Bioscience A/S, Herlev, Denmark.

Asger Reinstrup Bihlet (AR)

Nordic Bioscience A/S, Herlev, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH